Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
16/09/2025 22:17
Sept 16 (Reuters) - Kane Biotech Inc KNE.V: KANE BIOTECH COMPLETES U.S. FDA 510(K) SUBMISSION FOR REVYVE® ANTIMICROBIAL WOUND CLEANSER Source text: ID:nGNX78XzP8 Further company coverage: KNE.V ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update